All drug seeds for these programs are discovered by proprietary AI-based technology.

Project

Method

Target Indication

Development Stage

Partner

SO-001

Drug Repositioning

Taxane Resistance

Use patent (Japan/PCT)

SO-001-D

Derivative

Prostate Cancer (taxane resistance)

Lead Compound

Nanjing Medical Univ.

SO-001-D

Derivative

Breast Cancer (taxane resistance)

Lead Compound

Nanjing Medical Univ.

SO-001-D

Derivative

Uterine Cancer (taxane resistance)

Lead Compound

Nanjing Medical Univ.

SO-002(ALS)

Drug Repositioning

ALS

Use patent (Japan/PCT)

West China Hospital of Sichuan Univ.

SO-002(ALS)-D

Derivative

ALS

Nanjing Medical Univ.
West China Hospital of Sichuan Univ.

SO-002(FTLD)

Drug Repositioning

FTLD

Use patent (Japan/PCT)

West China Hospital of Sichuan Univ.

SO-002(FTLD)-D

Derivative

FTLD

Nanjing Medical Univ.
West China Hospital of Sichuan Univ.

SO-003

Drug Repositioning

sIBM

Nanjing Medical Univ.

SO-003-D

Derivative

sIBM

Nanjing Medical Univ.

Keio University

Drug Repositioning

Aging-associated diseases

in vivo assay

To Be Scheduled

Tokushima University

Drug Repositioning

Rare Cancer

in vitro assay

To Be Scheduled

Kanawaza University

Drug Repositioning

Immune Checkpoint Inhibitor Adjuvant

in vitro assay

To Be Scheduled